Halozyme Therapeutics Inc (HALO)
Financial leverage ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Total assets | US$ in thousands | 2,063,480 | 1,733,270 | 1,841,510 | 1,104,430 | 579,924 |
| Total stockholders’ equity | US$ in thousands | 363,821 | 83,808 | 169,798 | 196,953 | 151,047 |
| Financial leverage ratio | 5.67 | 20.68 | 10.85 | 5.61 | 3.84 |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $2,063,480K ÷ $363,821K
= 5.67
The financial leverage ratio of Halozyme Therapeutics Inc has shown significant fluctuations over the period from December 31, 2020, to December 31, 2024.
Starting at 3.84 in December 31, 2020, the financial leverage ratio increased to 5.61 by December 31, 2021, indicating a higher reliance on debt to finance its operations and investments.
Subsequently, the ratio surged to 10.85 by December 31, 2022, showing a substantial increase in financial leverage, which may suggest elevated financial risk and potentially higher interest costs.
By December 31, 2023, the financial leverage ratio soared to 20.68, reaching a concerning level that might raise solvency issues and impact the company's ability to meet its financial obligations.
However, by December 31, 2024, the ratio decreased to 5.67, indicating a partial alleviation of the high leverage seen in the previous year.
Overall, the fluctuating trend in the financial leverage ratio suggests varying levels of debt in the company's capital structure over the analyzed period, with the need for a close monitoring of debt management strategies to ensure financial stability and sustainability.
Peer comparison
Dec 31, 2024